Showing all 2 results
Leflunomide Tablets
FreeProduct Composition & Available Portfolio Strengths
We supply Leflunomide across the complete compendial strength matrix, enabling clinicians to manage both rapid initial loading cycles and long-term low-dose maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Leflunomide USP / BP / IP 10 mg Oral Solid Film-Coated Tablet Low-Dose Maintenance: Calibrated for mild-to-moderate maintenance blocks or patients exhibiting sensitive hepatic profiles. Leflunomide USP / BP / IP 20 mg Oral Solid Film-Coated Tablet The Core Commercial Volume: First-line international standard daily maintenance dose for active Rheumatoid and Psoriatic Arthritis. Leflunomide USP / BP / IP 100 mg Oral High-Mass Solid Tablet Initial Loading Regimen: High-potency format utilized exclusively for the rapid 3-day initial tissue saturation phase. Triamcinolone Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Uncoated Tablet, packed in highly secure, moisture-resistant Alu-PVC or opaque Alu-Alu blister strips to preserve the integrity of the steroidal API across high-humidity tropical climates.
Active Ingredient Strength Primary Clinical Use Triamcinolone IP/USP/BP 4 mg Standard Clinical Dose: Maintenance and flare-reduction therapy for severe inflammatory, allergic, and autoimmune disorders. Excipients Lactose Monohydrate / Magnesium Stearate / Microcrystalline Cellulose Diluent / Lubricant (Engineered for optimal compressibility and rapid gastric dispersion)
